Purchase this article with an account.
J. S. Yankelove, M. S. Benz, D. M. Brown, R. Y. Kim, R. H. Fish, T. P. Wong; Visual and Anatomic Outcomes of Serous Pigment Epithelial Detachments Treated With Ranibizumab. Invest. Ophthalmol. Vis. Sci. 2008;49(13):332.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate visual and anatomic outcomes in patients with serous pigment epithelial detachments treated with ranibizumab.
Retrospective review of medical records and diagnostic images.
Of 231 eyes newly diagnosed with exudative age-related macular degeneration (AMD) in a six month time period, 29 (12.5%) were found to have a serous detachment of the retinal pigment epithelium (RPE). Of these 29 eyes, 24 completed six months of treatment and 3 of 24 (12.5%) developed a tear of the RPE during the first six months of treatment. Among the patients with serous detachment of the RPE treated with ranibizumab, mean visual acuity improved from 20/100 at baseline to 20/57 at the six-month time point.
Patients with serous detachment of the RPE represent a distinct subgroup of patients with exudative AMD. Although these patients have a risk of tear of the RPE and attendant limitation in vision when treated with ranibizumab, patients treated with ranibizumab had a mean improvement in vision at the six-month time point.
This PDF is available to Subscribers Only